Approved in Canada.
http://addiction-dirkh.blogspot.com/2012/05/look-at-recent-study-of-cannabis-and.html
Two paragraphs here:
The leading wedge of the medical marijuana movement has traditionally
been centered on pot as medicine for the effects of chemotherapy, for
the treatment of glaucoma, and for certain kinds of neuropathic pain.
From there, the evidence for conditions treatable with marijuana quickly
becomes either anecdotal or based on limited studies. But pharmacologists have always been intrigued by the notion of treating certain neurologic conditions with cannabis. Sativex, which is sprayed under the tongue as a cannabis mist, has been approved
for use against multiple sclerosis, or MS, in Canada, the UK, and some
European countries. (In the U.S., parent company GW Pharma is seeking
FDA approval for the use of Sativex to treat cancer pain).
There is accumulating evidence that cannabinoid receptors may be
involved in controlling spasticity, and that anandamide, the brain’s
endogenous form of cannabis, is a specific antispasticity agent.
Come on, this is so simple, survivors with spasticity would flock to a research trial testing this.
We could have everyone clamoring for their grandparents needing marijuana to combat their stroke related spasticity.
No comments:
Post a Comment